JP2006273718A - Method for producing levofloxacin-1/2 hydrate - Google Patents

Method for producing levofloxacin-1/2 hydrate Download PDF

Info

Publication number
JP2006273718A
JP2006273718A JP2005090485A JP2005090485A JP2006273718A JP 2006273718 A JP2006273718 A JP 2006273718A JP 2005090485 A JP2005090485 A JP 2005090485A JP 2005090485 A JP2005090485 A JP 2005090485A JP 2006273718 A JP2006273718 A JP 2006273718A
Authority
JP
Japan
Prior art keywords
levofloxacin
water
hydrate
containing
volume
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2005090485A
Other languages
Japanese (ja)
Inventor
Eiji Imai
Hiroyuki Niwa
宏之 丹羽
英治 今井
Original Assignee
Shiono Chemical Co Ltd
シオノケミカル株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shiono Chemical Co Ltd, シオノケミカル株式会社 filed Critical Shiono Chemical Co Ltd
Priority to JP2005090485A priority Critical patent/JP2006273718A/en
Publication of JP2006273718A publication Critical patent/JP2006273718A/en
Application status is Pending legal-status Critical

Links

Abstract

PROBLEM TO BE SOLVED: To provide a method capable of changing a raw material of levofloxacin to levofloxacin 1/2 hydrate with high yield.
[MEANS FOR SOLVING PROBLEMS] Levofloxacin is a low water-containing lower alcohol containing water-containing lower alcohols or water-containing lower ketones having a water content of 0.14% by volume or more and less than 4% by volume, or concentrated ammonia water having a volume of 1 to 5% by volume. A process for producing levofloxacin 1/2 hydrate, which comprises recrystallization from alcohols or lower ketones containing aqueous ammonia.
[Selection figure] None

Description

  The present invention relates to a method for producing levofloxacin 1/2 hydrate, an antibacterial compound, and more specifically, levofloxacin 1/2 which obtains the 1/2 hydrate in high yield by recrystallizing levofloxacin. It relates to a method for producing hydrates.

  Levofloxacin ((S) -9-fluoro-3-methyl-10- (4-methyl-1-piperazinyl) -7-oxo-2,3-dihydro-7H-pyrido [1,2,3-de] [1 , 4] benzoxazine-6-carboxylic acid) is a compound having high antibacterial activity and high safety (see Patent Document 1), and its 1/2 hydrate is known as an excellent synthetic antibacterial agent. Yes.

  In this levofloxacin, in addition to the above-mentioned 1/2 hydrate, there are known monohydrates having different numbers of water of crystallization, and the presence of anhydrous crystals produced by dehydration from hydrates. In order to use as an antibacterial agent, it is necessary to make these into 1/2 hydrate.

  Conventionally, levofloxacin hemihydrate is obtained by mixing a crystal of levofloxacin monohydrate or anhydride (hereinafter referred to as “levofloxacin crude material”) with a mixed solvent of ethanol and diethyl ether or concentrated aqueous ammonia and ethanol (patented) It was obtained by recrystallization from 4-11% hydrous ethanol or hydrous acetone and crystallization.

  However, in the former method using the mixed solvent, levofloxacin crude raw material monohydrate (hereinafter simply referred to as “monohydrate”) is precipitated in addition to levofloxacin, which is a half hydrate, at the time of crystallization. However, this may be mixed. In the latter case, monohydrate may be precipitated and mixed, which is insufficient as a method for obtaining high-purity levofloxacin.

Japanese Patent Publication No. 3-27534

  Accordingly, there is a demand for the development of a method capable of changing the raw levofloxacin raw material to levofloxacin 1/2 hydrate with a high yield, and it is an object of the present invention to provide such a method.

  In order to solve the above problems, the present inventor has intensively studied a recrystallization method for obtaining levofloxacin 1/2 hydrate, and recrystallizes levofloxacin in a solvent having a very low water content. Thus, it was found that levofloxacin hemihydrate can be obtained stably and in high yield, and the present invention was completed.

  That is, the present invention provides levofloxacin 1/2 hydrate characterized by recrystallizing levofloxacin from water-containing lower alcohols or water-containing lower ketones having a water content of 0.14% by volume or more and less than 4% by volume. It is a manufacturing method.

  The present invention also provides levofloxacin / 1/2 water characterized by recrystallizing levofloxacin from ammonia water-containing lower alcohols or ammonia water-containing lower ketones containing 1 to 5% by volume of concentrated aqueous ammonia. It is a manufacturing method of Japanese products.

  According to the present invention, it is possible to convert a levofloxacin crude raw material to levofloxacin 1/2 hydrate in a high yield. Therefore, it can be used as a method for producing levofloxacin 1/2 hydrate from levofloxacin crude raw materials produced by various methods.

  In one embodiment of the present invention, levofloxacin 1/2 hydrate is obtained by recrystallizing a crude levofloxacin raw material from water-containing lower alcohols or water-containing lower ketones having a water content of 0.14% by volume or more and less than 4% by volume. It is a manufacturing method.

  The levofloxacin raw material to be used includes levofloxacin monohydrate and anhydride, but is not limited to this, and ½ hydrate containing impurities or mixed with the monohydrate or anhydride. Goods may be used as crude raw materials.

  The solvent that can be used for recrystallization (hereinafter referred to as “recrystallization solvent”) is not particularly limited as long as it is a solvent that is miscible with a small amount of water and can dissolve the levofloxacin raw material. For example, anhydrous methanol, anhydrous ethanol Examples thereof include lower alcohols such as isopropanol and butanol, and lower ketones such as acetone and methyl ethyl ketone.

  The recrystallization solvent needs to have a water content of 0.14% by volume or more and less than 4% by volume, and particularly preferably has a water content of 0.5% by volume or more and 2% by volume or less.

  When lower alcohols are used as the recrystallization solvent, the amount may be in the range of 4 to 8 times by weight with respect to the levofloxacin raw material, and usually 6 to 7 times by weight is desirable. When a lower ketone is used as the recrystallization solvent, it may be in the range of 10-50 times by weight of the raw levofloxacin raw material, and usually 20-30 times by weight is desirable. Furthermore, it is not necessary to use the above-mentioned amount from the beginning of the treatment, and the amount used for the recrystallization solvent may be adjusted to the above amount by dissolving in a larger amount of the recrystallization solvent in advance.

  The heating temperature for dissolving the levofloxacin crude raw material in this recrystallization solvent is in the range of 50 ° C to 80 ° C, and when the recrystallization solvent is a lower alcohol, a temperature of about 75 to 80 ° C is usually preferable. When the recrystallization solvent is a lower ketone, it is usually preferably 50 ° C to 60 ° C. Moreover, the cooling temperature after melt | dissolution is the range of 25 degreeC to -5 degreeC, and about 5 degreeC is preferable normally. The cooling time may range from 2 hours to 2 days and nights, preferably day and night.

  The recrystallization of levofloxacin 1/2 hydrate is preferably performed after the levofloxacin crude raw material is dissolved in a recrystallization solvent by heating, and then immediately cooled and allowed to stand for crystallization.

  On the other hand, in another embodiment of the present invention, concentrated levofloxacin raw material is concentrated 1% to 5% by volume, preferably 1.5% to 2.5% by volume of concentrated aqueous ammonia (27% aqueous ammonia). This is a process for producing levofloxacin 1/2 hydrate, which is recrystallized from ammonia water-containing lower alcohols or ammonia water-containing lower ketones.

  The invention according to this aspect can be carried out in the same manner as the invention according to the first aspect, except that the above ammonia water-containing lower alcohols or ammonia water-containing lower ketones are used as the recrystallization solvent. That is, the amount of solvent used, the heating temperature, and the cooling temperature may be substantially the same as described above.

  The water content of the ammonia water-containing lower alcohols or ammonia water-containing lower ketones (hereinafter referred to as “ammonia-containing recrystallization solvent”) containing concentrated ammonia water as described above is the same as the amount of concentrated ammonia water. In addition, the conditions of the invention of the first aspect can be generally satisfied.

  The method for producing levofloxacin 1/2 hydrate according to the present invention described above can include a purification step prior to the recrystallization and crystallization. For example, after the levofloxacin crude raw material is dissolved, a purification process such as decolorization can be added using activated carbon or the like.

  Further, levofloxacin hemihydrate obtained by the method of the present invention is dried to obtain a final product. It is preferable to perform the drying of the crystals under conditions that can remove only the solvent from the target product. For example, the drying temperature is about 20-45 ° C., preferably about 35-40 ° C., and the degree of vacuum is about 5-100 mmHg. Preferably it is about 5-10 mmHg. The drying time is preferably about 8 hours, and various drying methods such as an inverted conical screw agitation vacuum dryer, a vertical vibration vacuum dryer, or a box-type box vacuum dryer can be used as the drying method. Mention may be made of a drying method using a machine.

  The thus obtained levofloxacin 1/2 hydrate can be made into various forms of antibacterial agents by combining it with a known pharmaceutical carrier.

  EXAMPLES Next, although an Example is given and this invention is demonstrated still in detail, this invention is not restrict | limited at all by this.

Example 1
In a 100 mL eggplant-shaped flask, 10 g of levofloxacin crude raw material (anhydrous; water content: 0.994%) was weighed, and 2 v / v% water was added to absolute ethanol (water content: 0.14 v / v%). The solution made up to 65 mL was added and heated in a water bath. The crude levofloxacin raw material was dissolved at 77.3 ° C. and then allowed to cool. The mixture was allowed to cool at room temperature for one day and night, then filtered under reduced pressure and air-dried. 9.51 g of levofloxacin 1/2 hydrate was obtained.

Moisture value (Karl Fisher method Hiranuma Sangyo Co., Ltd. AQ-55C):
2.56% (theoretical value 2.43%)
Infrared absorption spectrum (IR-5000 manufactured by JASCO Corporation):
1724, 1005 Kaiser
Powder X-ray crystal diffraction (2θ):
6.5 °, 9.5 °, 12.9 °, 13.5 °, 19.2 °

Example 2
To a 100 mL eggplant-shaped flask, weighed 10.00 g of crude levofloxacin raw material (1/2 hydrate; moisture content 2.462%), added 70 mL of absolute ethanol (water content 0.14 v / v%), Heated in a water bath. Levofloxacin was dissolved at 79 ° C. and then allowed to cool. The mixture was allowed to cool at room temperature for 1 day and then filtered under reduced pressure and air-dried. 9.41 g of levofloxacin 1/2 hydrate was obtained.

Moisture value (Karl Fisher method Hiranuma Sangyo Co., Ltd. AQ-55C):
2.69% (theoretical value 2.43%)
Infrared absorption spectrum (IR-5000 manufactured by JASCO Corporation):
1724, 1006 Kaiser X-ray powder diffraction (2θ):
6.5 °, 9.5 °, 12.9 °, 13.5 °, 19.2 °

Example 3
In a 100 mL eggplant-shaped flask, weighed 10.00 g of levofloxacin crude raw material (anhydrous; water content 0.9994%), and added 2v / v% concentrated ammonia to absolute ethanol (water content 0.14 v / v%). A solution was made up to 60 mL by adding water and heated in a water bath. Since the crude levofloxacin was dissolved at 77.5 ° C., it was then allowed to cool. The mixture was allowed to cool at room temperature for 1 day and then filtered under reduced pressure and air-dried. 9.24 g of levofloxacin 1/2 hydrate was obtained.

Moisture value (Karl Fisher method Hiranuma Sangyo Co., Ltd. AQ-55C):
2.36% (theoretical value 2.43%)
Infrared absorption spectrum (IR-5000 manufactured by JASCO Corporation):
1724, 1006 Kaiser X-ray powder diffraction (2θ):
6.5 °, 9.5 °, 12.9 °, 13.5 °, 19.2 °

Example 4
A levofloxacin crude raw material (anhydrous; water content of 0.9994%) (1.000 g) was weighed into a 500 mL eggplant-shaped flask, and 260 mL of a solvent containing acetone (water content 0.07%) and water 2% was added thereto. In addition, it was heated in a water bath. Since the crude levofloxacin was dissolved at 51.6 ° C., it was then allowed to cool. The mixture was allowed to cool at room temperature for 1 day and then filtered under reduced pressure and air-dried. 6.80 g of levofloxacin 1/2 hydrate was obtained.

Moisture value (Karl Fisher method Hiranuma Sangyo Co., Ltd. AQ-55C):
2.688% (theoretical value 2.43%)
Infrared absorption spectrum (IR-5000 manufactured by JASCO Corporation):
1724, 1006 Kaiser X-ray powder diffraction (2θ):
6.5 °, 9.5 °, 12.8 °, 13.5 °, 19.1 °

According to the method of the present invention, levofloxacin / 1/2 hydrate can be efficiently obtained from a raw levofloxacin raw material, which is advantageous as a method for economically producing an antibacterial agent containing levofloxacin / 1/2 hydrate as an active ingredient. It can be used for.

more than

Claims (12)

  1.   A process for producing levofloxacin 1/2 hydrate, characterized by recrystallizing levofloxacin from water-containing lower alcohols or water-containing lower ketones having a water content of 0.14% by volume or more and less than 4% by volume.
  2.   The method for producing levofloxacin 1/2 hydrate according to claim 1, wherein the water content of the water-containing lower alcohol or water-containing lower ketone is 0.5 vol% or more and 2 vol% or less.
  3.   The method for producing levofloxacin 1/2 hydrate according to claim 1 or 2, wherein 4 to 8 times by weight of water-containing lower alcohol is used relative to levofloxacin.
  4.   The method for producing levofloxacin ½ hydrate according to claim 1 or 2, wherein 10 to 50 times by weight of water-containing lower ketone is used relative to levofloxacin.
  5.   The method for producing levofloxacin 1/2 hydrate according to any one of claims 1 to 4, wherein the levofloxacin is an anhydride or monohydrate of levofloxacin.
  6.   A process for producing levofloxacin 1/2 hydrate, characterized by recrystallizing levofloxacin from ammonia water-containing lower alcohols or ammonia water-containing lower ketones containing 1 to 5% by volume of concentrated aqueous ammonia.
  7.   The levofloxacin / 1/2 water according to claim 6, wherein the ammonia water-containing lower alcohol or the ammonia water-containing lower ketone contains 1.5% by volume to 2.5% by volume of concentrated ammonia water. Japanese recipes.
  8.   The method for producing levofloxacin 1/2 hydrate according to claim 6 or 7, wherein the lower alcohols containing ammonia water 4 to 8 times by weight thereof are used relative to levofloxacin.
  9.   The method for producing levofloxacin 1/2 hydrate according to claim 6 or 7, wherein 10 to 50 times by weight of an aqueous ammonia-containing lower ketone is used relative to levofloxacin.
  10.   The method for producing levofloxacin 1/2 hydrate according to any one of claims 6 to 9, wherein levofloxacin is an anhydride or monohydrate of levofloxacin.
  11.   Levofloxacin is dissolved at a temperature of 75-80 ° C. in water-containing ethanol having a water content of 6-7 times its weight and a water content of 0.5% by volume to 2% by volume. A process for producing the characteristic levofloxacin 1/2 hydrate.
  12. Levofloxacin was dissolved at a temperature of 75 to 80 ° C. in ethanol containing ammonia water containing 6 to 7 times its weight and concentrated ammonia water at 1.5 to 2.5% by volume. A process for producing levofloxacin 1/2 hydrate, characterized by cooling to room temperature.

JP2005090485A 2005-03-28 2005-03-28 Method for producing levofloxacin-1/2 hydrate Pending JP2006273718A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2005090485A JP2006273718A (en) 2005-03-28 2005-03-28 Method for producing levofloxacin-1/2 hydrate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005090485A JP2006273718A (en) 2005-03-28 2005-03-28 Method for producing levofloxacin-1/2 hydrate

Publications (1)

Publication Number Publication Date
JP2006273718A true JP2006273718A (en) 2006-10-12

Family

ID=37208812

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005090485A Pending JP2006273718A (en) 2005-03-28 2005-03-28 Method for producing levofloxacin-1/2 hydrate

Country Status (1)

Country Link
JP (1) JP2006273718A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010016851A1 (en) * 2008-08-02 2010-02-11 Apeloa-Kangyu Process for selectively producing a pyridobenzoxazine carboxylic acid hemihydrate

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04234890A (en) * 1990-03-01 1992-08-24 Dai Ichi Seiyaku Co Ltd Selective production of hydrate
WO2003028664A2 (en) * 2001-10-03 2003-04-10 Teva Pharmaceutical Industries Ltd. Preparation of levofloxacin and forms thereof
WO2003045329A2 (en) * 2001-11-29 2003-06-05 Teva Pharmaceutical Industries Ltd. Methods for the purification of levofloxacin
JP2006111561A (en) * 2004-10-14 2006-04-27 Ohara Yakuhin Kogyo Kk Method for producing 1/2 hydrate of antimicrobial agent

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04234890A (en) * 1990-03-01 1992-08-24 Dai Ichi Seiyaku Co Ltd Selective production of hydrate
WO2003028664A2 (en) * 2001-10-03 2003-04-10 Teva Pharmaceutical Industries Ltd. Preparation of levofloxacin and forms thereof
WO2003045329A2 (en) * 2001-11-29 2003-06-05 Teva Pharmaceutical Industries Ltd. Methods for the purification of levofloxacin
JP2006111561A (en) * 2004-10-14 2006-04-27 Ohara Yakuhin Kogyo Kk Method for producing 1/2 hydrate of antimicrobial agent

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010016851A1 (en) * 2008-08-02 2010-02-11 Apeloa-Kangyu Process for selectively producing a pyridobenzoxazine carboxylic acid hemihydrate
US7964723B2 (en) 2008-08-02 2011-06-21 Apeloa-Kangyu And practical process for exclusively producing (S)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido-[1,2,3,de][1,4]benzoxazine-6-carboxylic acid hemihydrate

Similar Documents

Publication Publication Date Title
ES2402808T3 (en) Methods of obtaining polymorphic forms of 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl) -piperidine-2,6-dione
KR950005302B1 (en) Crystalline hydrate of oral cephalosporin and its composition
EP2189459A1 (en) Stable crystalline salt of 5-methyll-(6S)-tetrahydrofolic acid
RU2186765C2 (en) Crystalline modifications of 2-amino-4-(4-fluoro- -benzylamino)-1-ethoxycarbonylaminobenzene and method of their preparing (variants)
RU2577331C2 (en) Crystalline base of minocycline and methods for obtaining thereof
JP2005139161A (en) Polymorph of rifaximin, method for producing the same, and its use in pharmaceutical preparation
JP2009149654A (en) Polymorphic compound
CN1203073C (en) Novel process for producing fused imidazopridine derivative and crystal form
CZ298170B6 (en) Polymorphous and amorphous modifications of 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylic acid and process of their preparation
ES2557281T3 (en) amide compounds, compositions and uses thereof
EP1919893A2 (en) Polymorphic forms of imatinib mesylate and processes for their preparation as well as of amorphous imatinib mesylate and form alpha
KR101719366B1 (en) Process for preparing amorphous refaximin and the amorphous refaximin thus obtained
BG60755B2 (en) Mometasonefuroate monohydrate, method for its preparation and pharmaceutical composition
NZ564023A (en) Crystalline modifications to pyraclostrobin
US5723625A (en) Process for the production of specific isomer mixtures from oxindole alkaloids
JPH0643400B2 (en) Preparation of stable transformation of torasemide
CS207647B2 (en) Method of making the crystallic hydrated form of the sodium salt of the oximin derivative of the 7-aminothiazolylacetamidocephalosporan acid
EP0444678B1 (en) Process for selectively producing hydrate crystals
CA2467427A1 (en) Process for the preparation of crystalline imipenem
JPH0770120A (en) Benzoxazine compound having stable crystal structure and its production
CN102046175A (en) Substituted heterocycle fused gamma-carbolines solid
Myz et al. Synthesis of co-crystals of meloxicam with carboxylic acids by grinding
CZ289234B6 (en) 5-Acetamido-2,3,4,5-tetradeoxy-4-guanidino-D-glycero-D-galacto-non-2-enopyranoasonic acid in crystalline form, process of its preparation and pharmaceutical preparations based thereon
US6706710B2 (en) Form of (R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide
RU2323214C2 (en) Methods for preparing derivatives of 1-[2-(benzimidazol-1-yl)quinolin-8-yl]piperidin-4-ylamine

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080208

A131 Notification of reasons for refusal

Effective date: 20110719

Free format text: JAPANESE INTERMEDIATE CODE: A131

A02 Decision of refusal

Effective date: 20111220

Free format text: JAPANESE INTERMEDIATE CODE: A02